Compare iShares Bitcoin Trust (IBIT) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs 10X Genomics Inc — how do they compare? iShares Bitcoin Trust trades at $46.55 (market cap $67.31B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: iShares Bitcoin Trust is far larger — about 6.7× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and 10X Genomics Inc for 91 Days on average.
| IBIT | TXG | |
|---|---|---|
Market Cap | $67.31B | $10.07B |
Volume | 56,154,544 | 5,657,286 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $97.74 |
52-Week Low | $33.29 | $11.48 |
Typical Hold Time | 40 Days | 91 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.26, down 2.01% today amid bearish technical signals. The stock faces resistance at $47-$48 with support at $44-$46. Recent news highlights significant institutional inflows, including a $196 million single-day inflow on October 1, 2026, reflecting renewed investor confidence despite current price weakness.
The outlook remains cautious with technical indicators showing bearish momentum, though strong institutional interest suggests potential recovery. Key risks include market volatility and ETF fee structures, while analyst sentiment appears mixed with ongoing monitoring of Bitcoin market dynamics influencing stock performance.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
